Table 2

Active clinical trials of targeted therapy in uterine serous carcinoma

NCT number	Phase	Molecular target	Investigational agent	Reference
03552471	I	FR-α PARP	Mirvetuximab Rucaparib	69
03120624	I	IFN-β receptor	IFN-β by viral vector	70
02142803	I	mTORC VEGF	MLN0128 Bevacizumab	71
01935973	I	MEK AKT	Trametinib GSK2141795	72
01935934	II	VEGF	Cabozantinib	73
04080284	II	PARP	Niraparib	67
03668340	II	WEE1	Adavosertib	74
02874430	II	AMPK	Metformin	75
02491099	II	HER2	Afatinibin	61
03914612	III	PDL1	Pembrolizumab	65

AKT also known as protein kinase B.
AMPK, AMP-activated protein kinase; FR, folate receptor; IFN, Interferon; MEK, mitogen-activated protein kinase; mTORC, mammalian target of rapamycin; PARP, poly(ADP-ribose) polymerase; PDL-1, programed death ligand 1; VEGF, vascular endothelial growth factor.